Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation

Clinical Lymphoma and Myeloma

Volumn 9, Issue 5, 2009, Pages

  Pingali, Sai Ravi Kiran ^a   Mathiason, Michelle ^a   Lovrich, Steven ^a   Go, Ronald ^b  

^a Gundersen Lutheran Medical Foundation   (United States)

^b Gundersen Lutheran Health System   (United States)

Author keywords

Erythrocytosis; Myelofibrosis; Phlebotomy; Polycythemia vera; Sleep apnea

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; JANUS KINASE 2; MESSENGER RNA; NILOTINIB;

ADULT; ARTICLE; BONE MARROW BIOPSY; CANCER REGRESSION; CASE REPORT; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CONGESTIVE HEART FAILURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FLUID RETENTION; GENE MUTATION; GENE TRANSLOCATION; HUMAN; HUMAN TISSUE; INTERSTITIAL PNEUMONIA; LOOSE FECES; MALE; MYELOPROLIFERATIVE DISORDER; PHLEBOTOMY; PHYSICAL EXAMINATION; POLYCYTHEMIA VERA; RISK FACTOR; SIDE EFFECT;

EID: 70350633820     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.080     Document Type: Article

References (36)

1. Tefferi A, Gilliland DG. The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc 2005; 80:947-958
2. Passamonti F, Malabarba L, Orlandi E, et al. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica 2003; 88:13-18
3. Cervantes F, Alvarez-Larran A, Talarn C, et al. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol 2002; 118:786-790
4. Kemp NH, Stafford JL, Tanner R. Chromosome studies during early and terminal chronic myeloid leukaemia. BMJ 1964; 1:1010-1014.
5. Koulischer L, Fruhling J, Henry J. Cytogenetic findings in Vaquez' disease. Eur J Cancer 1967; 3:193-201.
6. Hoppin EC, Lewis JP. Polycythemia rubra vera progressing to Ph1-positive chronic myelogenous leukemia. Ann Intern Med 1975; 83:820-823
7. Haq AU. Transformation of polycythemia vera to Ph-positive chronic myelogenous leukemia. Am J Hematol 1990; 35:110-113
8. Jantunen E, Nousiainen T. The progression of polycythemia vera to chronic myeloid leukemia. Duodecim 1991; 107:641-644
9. Roth AD, Oral A, Przepiorka D, et al. Chronic myelogenous leukemia and acute lymphoblastic leukemia occurring in the course of polycythemia vera. Am J Hematol 1993; 43:123-128.
10. Ganti AK, Potti A, Mehdi SA. Chromosomal anomalies in two coexistent myeloproliferative disorders. Cancer Genet Cytogenet 2003; 145:172-175
11. Curtin NJ, Campbell PJ, Green AR. The Philadelphia translocation and pre-existing myeloproliferative disorders. Br J Haematol 2005; 128:734-736.
12. Wahlin A, Golovleva I. Emergence of Philadelphia positive chronic myeloid leukaemia during treatment with hydroxyurea for Philadelphia negative essential thrombocythaemia. Eur J Haematol 2003; 70:240-241
13. Mauro MJ, Loriaux M, Deininger MW. Ph-positive and -negative myeloproliferative syndromes may co-exist. Leukemia 2004; 18:1305-1307
14. Cesar JM, Cabello P, Ferro T, et al. Emergence of chronic myelogenous leukemia in a patient with primary thrombocythemia and absence of BCR/ABL rearrangement. Cancer Genet Cytogenet 2006; 167:74-77
15. Araki N, Takimoto R, Fujimi A, et al. Reappearance of t(12;17)-positive primary myelofibrosis following ph+ CML cell reduction by imatinib. Rinsho Ketsueki 2007; 48:518-523
16. Bennett M, Chubar E. Chronic myeloid leukemia evolving after idiopathic myelofibrosis. Isr Med Assoc J 2007; 9:562-563
17. Scott LM, Campbell PJ, Baxter EJ, et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood 2005; 106:2920-2921
18. Hussein K, Bock O, Seegers A, et al. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood 2007; 109:4106-4107
19. Bornhauser M, Mohr B, Oelschlaegel U, et al. Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia 2007; 21:1824-1826.
20. Kramer A, Reiter A, Kruth J, et al. JAK2-V617F mutation in a patient with Philadelphia- chromosome-positive chronic myeloid leukaemia. Lancet Oncol 2007; 8:658-660
21. Bocchia M, Vannucchi AM, Gozzetti A, et al. Insights into JAK2-V617F mutation in CML. Lancet Oncol 2007; 8:864-866
22. Mirza I, Frantz C, Clarke G, et al. Transformation of polycythemia vera to chronic myelogenous leukemia. Arch Pathol Lab Med 2007; 131:1719-1724
23. Pardini S, Fozza C, Contini S, et al. A case of coexistence between JAK2V617F and BCR /ABL. Eur J Haematol 2008; 81:75-76
24. Kim YK, Shin MG, Kim HR, et al. Simultaneous occurrence of the JAK2V617F mutation and BCR-ABL gene rearrangement in patients with chronic myeloproliferative disorders. Leuk Res 2008; 32:993-995
25. Jallades L, Hayette S, Tigaud I, et al. Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis. Leuk Res 2008; 32:1608-1610
26. De Conchon MR, Costa JL, Novaes MM, et al. Simultaneous detection of JAK2 V617F mutation and bcr-abl translocation in a patient with chronic myelogenous leukemia. Int J Hematol 2008; 88:243-245
27. Cambier N, Renneville A, Cazaentre T, et al. JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders. Leukemia 2008; 22:1454-1455
28. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005; 106:3370-3373
29. Saviola A, Fiorani C, Ferrara L, et al. Transition of polycythemia vera to chronic myelogenous leukaemia. Eur J Haematol 2005; 75:264-266
30. Inami M, Inokuchi K, Okabe M, et al. Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia 2007; 21:1103-1104
31. Nicoara S, Butoianu E, Brosteanu R. Specificity of the Ph1 chromosome. Lancet 1967; 2:1312-1313
32. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008; 112:45-52.
33. Preston DL, Kusumi S, Tomonaga M, et al. Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiat Res 1994; 137(suppl):S68-97.
34. Landgren O, Goldin LR, Kristinsson SY, et al. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. Blood 2008; 112:2199-2204
35. Plo I, Nakatake M, Malivert L, et al. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood 2008; 112:1402-1412
36. Xie S, Wang Y, Liu J, et al. Involvement of Jak2 tyrosine phosphorylation in bcrabl transformation. Oncogene 2001; 20:6188-6195